Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Annu Rev Biochem ; 85: 573-97, 2016 Jun 02.
Artículo en Inglés | MEDLINE | ID: mdl-27023845

RESUMEN

Epidermal growth factor (EGF) and insulin receptor tyrosine kinases (RTKs) exemplify how receptor location is coupled to signal transduction. Extracellular binding of ligands to these RTKs triggers their concentration into vesicles that bud off from the cell surface to generate intracellular signaling endosomes. On the exposed cytosolic surface of these endosomes, RTK autophosphorylation selects the downstream signaling proteins and lipids to effect growth factor and polypeptide hormone action. This selection is followed by the recruitment of protein tyrosine phosphatases that inactivate the RTKs and deliver them by membrane fusion and fission to late endosomes. Coincidentally, proteinases inside the endosome cleave the EGF and insulin ligands. Subsequent inward budding of the endosomal membrane generates multivesicular endosomes. Fusion with lysosomes then results in RTK degradation and downregulation. Through the spatial positioning of RTKs in target cells for EGF and insulin action, the temporal extent of signaling, attenuation, and downregulation is regulated.


Asunto(s)
Factor de Crecimiento Epidérmico/genética , Receptores ErbB/genética , Regulación de la Expresión Génica , Insulina/genética , Proteínas Tirosina Quinasas/genética , Transducción de Señal , Membrana Celular/metabolismo , Endocitosis , Endosomas/metabolismo , Factor de Crecimiento Epidérmico/metabolismo , Receptores ErbB/metabolismo , Retroalimentación Fisiológica , Humanos , Insulina/metabolismo , Membranas Intracelulares/metabolismo , Fosforilación , Transporte de Proteínas , Proteínas Tirosina Fosfatasas/genética , Proteínas Tirosina Fosfatasas/metabolismo , Proteínas Tirosina Quinasas/metabolismo
2.
Biochemistry ; 49(15): 3213-5, 2010 Apr 20.
Artículo en Inglés | MEDLINE | ID: mdl-20232875

RESUMEN

We combined oxygen channeling assays with two distinct chemiluminescent beads to detect simultaneously protein phosphorylation and interaction events that are usually monitored separately. This novel method was tested in the ERK1/2 MAP kinase pathway. It was first used to directly monitor dissociation of MAP kinase ERK2 from MEK1 upon phosphorylation and to evaluate MAP kinase phosphatase (MKP) selectivity and mechanism of action. In addition, MEK1 and ERK2 were probed with an ATP competitor and an allosteric MEK1 inhibitor, which generated distinct phosphorylation-interaction patterns. Simultaneous monitoring of protein-protein interactions and substrate phosphorylation can provide significant mechanistic insight into enzyme activity and small molecule action.


Asunto(s)
Proteínas/metabolismo , Adenosina Trifosfato/metabolismo , Unión Competitiva , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Consumo de Oxígeno , Fosforilación , Proteínas/química
3.
Anal Biochem ; 404(1): 45-51, 2010 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-20434426

RESUMEN

Mutations within the LRRK2 (leucine-rich repeat kinase 2) gene predispose humans to develop late-onset Parkinson's disease (PD). The most prevalent of these mutations, G2019S, has been shown to increase LRRK2 kinase activity. Therefore, the discovery of small molecule inhibitors of LRRK2(G2019S) through high-throughput screening (HTS) may provide a novel therapeutic strategy for treating PD. Current biochemical assays monitoring the activity of LRRK2(G2019S) either are radioactive or use short peptidic substrates. Here we describe the development and optimization of a novel HTS AlphaScreen assay for measuring the catalytic activity of full-length LRRK2(G2019S) using its putative physiological protein substrate moesin. The high sensitivity of this optimized 384-well assay allowed the use of enzyme concentrations as low as 0.75nM. The estimated apparent K(m) value for adenosine triphosphate (6 microM) using the glutathione S-transferase-moesin substrate was much lower than the one previously reported using LRRKtide, a synthetic peptide derived from moesin. Testing of nonselective kinase inhibitors (staurosporine, H-1152, and Y-27632) generated potencies consistent with published data. Finally, robotic validation of the assay yielded an average Z' factor of 0.80. Overall, these results indicate that the present HTS AlphaScreen assay might provide a more relevant biochemical approach for the discovery of novel LRRK2(G2019S) inhibitors.


Asunto(s)
Inmunoensayo/métodos , Proteínas de Microfilamentos/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Adenosina Trifosfato/metabolismo , Sustitución de Aminoácidos , Ensayos Analíticos de Alto Rendimiento , Humanos , Cinética , Proteína 2 Quinasa Serina-Treonina Rica en Repeticiones de Leucina , Mutagénesis Sitio-Dirigida , Inhibidores de Proteínas Quinasas/química , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Serina-Treonina Quinasas/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Factores de Tiempo
4.
Curr Genomics ; 10(2): 93-101, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19794881

RESUMEN

Global deciphering of signal transduction pathways represents a new challenge of the post-genomic era. However, for the majority of these signaling pathways the role(s), the function(s) and the interaction(s) of the signaling intermediates remain to be characterized in an integrated fashion. The global molecular study of cell signaling pathways and networks consequently requires sensitive, robust technologies which may allow in addition multi-parallel and highthroughput applications. The Alphascreen technology, relying on a bead-based homogenous approach, constitutes a valuable tool to detect and quantify a wide range of signaling events such as enzymatic activities or biomolecular interactions. In this article, we exhaustively review the literature and report the broad spectrum of Alphascreen-based applications in the study of signal transduction pathways.

5.
Mol Neurodegener ; 7: 31, 2012 Jun 26.
Artículo en Inglés | MEDLINE | ID: mdl-22734645

RESUMEN

BACKGROUND: The Aß peptide that accumulates in Alzheimer's disease (AD) is derived from amyloid precursor protein (APP) following proteolysis by ß- and γ-secretases. Substantial evidence indicates that alterations in APP trafficking within the secretory and endocytic pathways directly impact the interaction of APP with these secretases and subsequent Aß production. Various members of the low-density lipoprotein receptor (LDLR) family have been reported to play a role in APP trafficking and processing and are important risk factors in AD. We recently characterized a distinct member of the LDLR family called LDLR-related protein 10 (LRP10) that shuttles between the trans-Golgi Network (TGN), plasma membrane (PM), and endosomes. Here we investigated whether LRP10 participates in APP intracellular trafficking and Aß production. RESULTS: In this report, we provide evidence that LRP10 is a functional APP receptor involved in APP trafficking and processing. LRP10 interacts directly with the ectodomain of APP and colocalizes with APP at the TGN. Increased expression of LRP10 in human neuroblastoma SH-SY5Y cells induces the accumulation of mature APP in the Golgi and reduces its presence at the cell surface and its processing into Aß, while knockdown of LRP10 expression increases Aß production. Mutations of key motifs responsible for the recycling of LRP10 to the TGN results in the aberrant redistribution of APP with LRP10 to early endosomes and a concomitant increase in APP ß-cleavage into Aß. Furthermore, expression of LRP10 is significantly lower in the post-mortem brain tissues of AD patients, supporting a possible role for LRP10 in AD. CONCLUSIONS: The present study identified LRP10 as a novel APP sorting receptor that protects APP from amyloidogenic processing, suggesting that a decrease in LRP10 function may contribute to the pathogenesis of Alzheimer's disease.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Precursor de Proteína beta-Amiloide/metabolismo , Proteínas Relacionadas con Receptor de LDL/genética , Procesamiento Proteico-Postraduccional/fisiología , Enfermedad de Alzheimer/genética , Secretasas de la Proteína Precursora del Amiloide/genética , Secretasas de la Proteína Precursora del Amiloide/metabolismo , Precursor de Proteína beta-Amiloide/genética , Animales , Membrana Celular/metabolismo , Células Cultivadas , Endosomas/genética , Endosomas/metabolismo , Aparato de Golgi/metabolismo , Humanos , Proteínas Relacionadas con Receptor de LDL/metabolismo , Ratones , Transporte de Proteínas , Red trans-Golgi/metabolismo
6.
Proteomics Clin Appl ; 1(9): 922-33, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21136747

RESUMEN

Over the past 75 years, antibodies have gone from being recognized as disease biomarkers to being used as very powerful therapeutic tools. This evolution has been accelerated by the identification of mAb and the extensive use of immunological tools both at fundamental and clinical levels. In this review, we evaluate how antibodies can be used to assess the proteome of cells or tissues and their relevance for clinical applications. These antibody-based proteomics approaches also require analytical and technological pipelines as well as specific enabling tools which are described. Our first objective was to establish how large-scale datasets (provided by high-throughput studies such as proteomics and transcriptomics) can be integrated with literature searches and clinical data to identify potentially relevant markers against which antibodies should be raised. Then based on an extensive literature review and our experience, we compare the methodologies developed to produce specific antibodies either in vivo or in vitro. This is followed by the description of the validation tools currently available and it also includes the use of antibody-based approaches in the establishment of molecular signatures utilized at the bench and soon available for bedside use.

7.
Gastroenterology ; 129(6): 2032-46, 2005 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16344069

RESUMEN

BACKGROUND & AIMS: The pancreatic acinar cell is known to regulate exocytosis, total protein synthesis, and secretory protein transport in response to a secretory stimulus. Whether secretory vesicle formation also is regulated is unclear. In this study, we determined whether agonist stimulation induces morphologic alterations in the acinar cell Golgi apparatus, and we evaluated the role of the vesicle severing protein dynamin. METHODS: Changes in Golgi structural integrity by examining the distribution of various Golgi and TGN lipid and protein markers in live and fixed cells on stimulation with cholecystokinin were noted in a primary pancreatic acinar cell model. Multiple dynamin reagents were used to examine the distribution and function of this molecular pinchase in resting and stimulated cells. RESULTS: Regulated secretion in acinar cells induced (1) marked fragmentation of the trans-Golgi network (TGN) that corresponded temporally with an increase in cytoplasmic calcium whereas pre-TGN compartments of the Golgi and regions of the TGN involved in the generation of constitutively trafficking vesicles were unaffected by agonist, and (2) significant recruitment of dynamin to the acinar cell Golgi apparatus that appeared to potentiate fragmentation of the TGN. CONCLUSIONS: These results suggest that the TGN is a dynamic organelle that fragments in response to cholecystokinin stimulation, a process that may contribute to zymogen granule formation.


Asunto(s)
Colagogos y Coleréticos/farmacología , Aparato de Golgi/efectos de los fármacos , Páncreas Exocrino/citología , Sincalida/farmacología , Animales , Biomarcadores , Células Cultivadas , Dinaminas/metabolismo , Aparato de Golgi/metabolismo , Aparato de Golgi/ultraestructura , Lípidos/química , Páncreas Exocrino/efectos de los fármacos , Ratas , Vesículas Secretoras/metabolismo , Vesículas Secretoras/ultraestructura , Red trans-Golgi/efectos de los fármacos , Red trans-Golgi/metabolismo , Red trans-Golgi/ultraestructura
8.
J Biol Chem ; 277(49): 47551-6, 2002 Dec 06.
Artículo en Inglés | MEDLINE | ID: mdl-12356748

RESUMEN

The presence of intracellular aggregates that contain Cu/Zn superoxide dismutase (SOD1) in spinal cord motor neurons is a pathological hallmark of amyotrophic lateral sclerosis (ALS). Although SOD1 is abundant in all cells, its half-life in motor neurons far exceeds that in any other cell type. On the basis of the premise that the long half-life of the protein increases the potential for oxidative damage, we investigated the effects of oxidation on misfolding/aggregation of SOD1 and ALS-associated SOD1 mutants. Zinc-deficient wild-type SOD1 and SOD1 mutants were extremely prone to form visible aggregates upon oxidation as compared with wild-type holo-protein. Oxidation of select histidine residues that bind metals in the active site mediates SOD1 aggregation. Our results provide a plausible model to explain the accumulation of SOD1 aggregates in motor neurons affected in ALS.


Asunto(s)
Esclerosis Amiotrófica Lateral/enzimología , Superóxido Dismutasa/química , Superóxido Dismutasa/metabolismo , Aminoácidos/metabolismo , Esclerosis Amiotrófica Lateral/genética , Esclerosis Amiotrófica Lateral/metabolismo , Benzotiazoles , Sitios de Unión , Cromatografía Liquida , Dicroismo Circular , Eritrocitos/enzimología , Humanos , Concentración de Iones de Hidrógeno , Luz , Microscopía de Fuerza Atómica , Modelos Moleculares , Mutagénesis Sitio-Dirigida , Mutación , Neuronas/metabolismo , Oxígeno/metabolismo , Unión Proteica , Pliegue de Proteína , Dispersión de Radiación , Superóxido Dismutasa/genética , Tiazoles/metabolismo , Zinc/metabolismo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda